Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2005

01-06-2005

Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort

Authors: Kelly-Anne Phillips, Phyllis N. Butow, Ailsa E. Stewart, Jiun-Horng Chang, Prue C. Weideman, Melanie A. Price, Sue Anne McLachlan, kConFab Investigators, Geoffrey J. Lindeman, Michael J. McKay, Michael L. Friedlander, John L. Hopper

Published in: Familial Cancer | Issue 2/2005

Login to get access
Metadata
Title
Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort
Authors
Kelly-Anne Phillips
Phyllis N. Butow
Ailsa E. Stewart
Jiun-Horng Chang
Prue C. Weideman
Melanie A. Price
Sue Anne McLachlan
kConFab Investigators
Geoffrey J. Lindeman
Michael J. McKay
Michael L. Friedlander
John L. Hopper
Publication date
01-06-2005
Publisher
Kluwer Academic Publishers
Published in
Familial Cancer / Issue 2/2005
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-004-6129-x

Other articles of this Issue 2/2005

Familial Cancer 2/2005 Go to the issue

OriginalPaper

Informing one’s family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study

OriginalPaper

Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations

OriginalPaper

Screening for exonic copy number mutations at MSH2 and MLH1 by MAPH

OriginalPaper

The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li–Fraumeni-like kindreds

Letter to the editor

The BRCA1 exon 13 duplication in the Swedish population

OriginalPaper

The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits